As Introduced

133rd General Assembly

Regular Session

2019-2020

H. B. No. 700

Representatives Holmes, A., Crossman

A BILL

То	amend sections 1751.91, 3719.063, 3923.89,	1
	4723.52, 4729.283, 4729.45, 4729.75, 4729.80,	2
	4729.84, 4730.56, 4731.83, 5119.363, and	3
	5164.14; to amend, for the purpose of adopting a	4
	new section number as indicated in parentheses,	5
	section 3719.064 (3719.067); and to enact new	6
	section 3719.064 and sections 3719.065, 3727.27,	7
	3727.61, 4729.791, 4731.92, and 5119.441 of the	8
	Revised Code regarding making addiction	9
	treatment widely available.	10

BE IT ENACTED BY THE GENERAL ASSEMBLY OF THE STATE OF OHIO:

Section 1. That sections 1751.91, 3719.063, 3923.89,	11
4723.52, 4729.283, 4729.45, 4729.75, 4729.80, 4729.84, 4730.56,	12
4731.83, 5119.363, and 5164.14 be amended; section 3719.064	13
(3719.067) be amended for the purpose of adopting a new section	14
number as indicated in parentheses; and new section 3719.064 and	15
sections 3719.065, 3727.27, 3727.61, 4729.791, 4731.92, and	16
5119.441 of the Revised Code be enacted to read as follows:	17

Sec. 1751.91. A health insuring corporation may provide18payment or reimbursement to a pharmacist for providing a health19

care service to a patient if both of the following are the case:	20
(A) The pharmacist provided the health care service to the	21
patient in accordance with Chapter 4729. of the Revised Code,	22
including any of the following services:	23
(1) Managing drug therapy under a consult agreement with a	24
physician pursuant to section 4729.39 of the Revised Code;	25
(2) Administering immunizations in accordance with section	26
4729.41 of the Revised Code;	27
(3) Administering drugs in accordance with section 4729.45	28
or 4731.92 of the Revised Code.	20
	2.0
(B) The patient's individual or group health insuring	30 31
corporation policy, contract, or agreement provides for payment	
or reimbursement of the service.	32
Sec. 3719.063. In the absence of gross negligence or	33
Sec. 3719.063. In the absence of gross negligence or intentional misconduct, a person who administers the drug	33 34
intentional misconduct, a person who administers the drug	34
intentional misconduct, a person who administers the drug naltrexone by injection, the person's employer, and the facility	34 35
intentional misconduct, a person who administers the drug naltrexone by injection, the person's employer, and the facility at which the drug is administered are not liable in any civil	34 35 36
intentional misconduct, a person who administers the drug naltrexone by injection, the person's employer, and the facility at which the drug is administered are not liable in any civil action or subject to criminal prosecution or professional	34 35 36 37
intentional misconduct, a person who administers the drug naltrexone by injection, the person's employer, and the facility at which the drug is administered are not liable in any civil action or subject to criminal prosecution or professional discipline for any injury or damage caused by the injection or	34 35 36 37 38
intentional misconduct, a person who administers the drug naltrexone by injection, the person's employer, and the facility at which the drug is administered are not liable in any civil action or subject to criminal prosecution or professional discipline for any injury or damage caused by the injection or drug if all of the following conditions are met:	34 35 36 37 38 39
<pre>intentional misconduct, a person who administers the drug naltrexone by injection, the person's employer, and the facility at which the drug is administered are not liable in any civil action or subject to criminal prosecution or professional discipline for any injury or damage caused by the injection or drug if all of the following conditions are met:</pre>	34 35 36 37 38 39 40
<pre>intentional misconduct, a person who administers the drug naltrexone by injection, the person's employer, and the facility at which the drug is administered are not liable in any civil action or subject to criminal prosecution or professional discipline for any injury or damage caused by the injection or drug if all of the following conditions are met:</pre>	34 35 36 37 38 39 40 41
<pre>intentional misconduct, a person who administers the drug naltrexone by injection, the person's employer, and the facility at which the drug is administered are not liable in any civil action or subject to criminal prosecution or professional discipline for any injury or damage caused by the injection or drug if all of the following conditions are met: (A) The individual to whom the drug is administered is unable to have it administered as follows: (1) By a person who routinely administers the drug to the</pre>	34 35 36 37 38 39 40 41 42
<pre>intentional misconduct, a person who administers the drug naltrexone by injection, the person's employer, and the facility at which the drug is administered are not liable in any civil action or subject to criminal prosecution or professional discipline for any injury or damage caused by the injection or drug if all of the following conditions are met: (A) The individual to whom the drug is administered is unable to have it administered as follows: (1) By a person who routinely administers the drug to the individual;</pre>	34 35 36 37 38 39 40 41 42 43
<pre>intentional misconduct, a person who administers the drug naltrexone by injection, the person's employer, and the facility at which the drug is administered are not liable in any civil action or subject to criminal prosecution or professional discipline for any injury or damage caused by the injection or drug if all of the following conditions are met:</pre>	34 35 36 37 38 39 40 41 42 43 44

(B) The person who administers the drug under this section	47
is legally authorized to administer it by injection but is not	48
	49
the prescriber of the drug or one who routinely administers it	
to the individual.	50
(C) The drug is provided to the person who administers it	51
under this section in either of the following ways:	52
(1) By the individual to whom it is administered;	53
(2) By the pharmacy that has a record of a prescription	54
for the drug in the name of the individual to whom it is	55
administered.	56
(D) The person who administers the drug under this section	57
is authorized to do so by that person's employer or the facility	58
at which the drug is administered.	59
(E) This section does not apply in the case of an	60
individual who administers an injectable long-acting or	61
extended-release form of naltrexone in accordance with a	62
protocol as authorized by section 4731.92 of the Revised Code.	63
Sec. 3719.064. (A) As used in this section and in section	64
3719.065 of the Revised Code, "prescriber" means any of the	65
following:	66
(1) An advanced practice registered nurse who holds a	67
current, valid license issued under Chapter 4723. of the Revised	68
Code and is designated as a clinical nurse specialist, certified	69
nurse-midwife, or certified nurse practitioner;	70
(2) A physician authorized under Chapter 4731. of the	71
<u>Revised Code to practice medicine and surgery or osteopathic</u>	72
medicine and surgery;	73
(3) A physician assistant who is licensed under Chapter	74

4730. of the Revised Code, holds a valid prescriber number	75
issued by the state medical board, and has been granted	76
physician-delegated prescriptive authority.	77
	7.0
(B) To the extent permitted by federal law, a prescriber_	78
who prescribes opioid analgesics shall offer, during business	79
hours at the location where the prescriber practices,	80
administration of injectable long-acting or extended-release	81
forms of naltrexone. The administration may be delegated in	82
accordance with rules adopted under section 4723.48, 4730.203,	83
or 4731.053 of the Revised Code, as applicable.	84
	0.5
<u>A prescriber who delegates the administration of</u>	85
injectable long-acting or extended-release forms of naltrexone	86
is not liable in damages to any person or government entity in a	87
civil action for injury, death, or loss to person or property	88
that allegedly arises from an act or omission of the delegate in	89
administering naltrexone, if the prescriber delegates in	90
accordance with this chapter and rules adopted under Chapter	91
4723., 4730., or 4731. of the Revised Code, as applicable.	92
Sec. 3719.065. (A) A prescriber who prescribes methadone	93
or noninjectable forms of buprenorphine shall taper the patient	94
off the drug within sixty days. If such tapering is not	95
possible, only daily doses of those drugs may be personally	96
furnished by the prescriber thereafter.	97
(B) Any prescriber who has obtained a waiver to treat	98
opioid addiction as provided under the federal Drug Addiction	99
Treatment Act of 2000 (DATA 2000), 21 U.S.C. 823(g), is required	100
to have completed training regarding injectable long-acting or	101
extended-release forms of naltrexone and burprenorphine. The	102
state board of pharmacy shall review training programs,	103
including training programs provided by organizations identified	104

in DATA 2000, and approve, for purposes of this section, those it determines meet the requirement of providing the training as	105 106
specified in this division.	107
Sec. 3719.064 3719.067. (A) As used in this section:	108
(1) "Medication-assisted treatment" has the same meaning	109
as in section 340.01 of the Revised Code.	110
(2) "Prescriber" means any of the following:	111
(a) An advanced practice registered nurse who holds a	112
current, valid license issued under Chapter 4723. of the Revised	113
Code and is designated as a clinical nurse specialist, certified	114
nurse-midwife, or certified nurse practitioner;	115
(b) A physician authorized under Chapter 4731. of the	116
Revised Code to practice medicine and surgery or osteopathic	117
medicine and surgery;	118
(c) A physician assistant who is licensed under Chapter	119
4730. of the Revised Code, holds a valid prescriber number	120
issued by the state medical board, and has been granted	121
physician-delegated prescriptive authority.	122
(3) "Qualifying practitioner" has the same meaning as in	123
section 303(g)(2)(G)(iii) of the "Controlled Substances Act of	124
1970," 21 U.S.C. 823(g)(2)(G)(iii), as amended.	125
(B) Before initiating medication-assisted treatment, a	126
prescriber shall give the patient or the patient's	127
representative information about all drugs approved by the	128
United States food and drug administration for use in	129
medication-assisted treatment. The information must be provided	130
both orally and in writing. The prescriber or the prescriber's	131
delegate shall note in the patient's medical record when this	132

information was provided and make the record available to 133 employees of the board of nursing or state medical board on 134 their request. 135

If the prescriber is not a qualifying practitioner and the 136 patient's choice is opioid treatment and the prescriber 137 determines that such treatment is clinically appropriate and 138 meets generally accepted standards of medicine, the prescriber 139 shall refer the patient to an opioid treatment program licensed 140 under section 5119.37 of the Revised Code or a qualifying 141 practitioner. The prescriber or the prescriber's delegate shall 142 143 make a notation in the patient's medical record naming the program or practitioner to whom the patient was referred and 144 specifying when the referral was made. 145

Sec. 3727.27. If a hospital fails to treat drug addiction 146 with at least eight inpatient beds and an outpatient program, as 147 determined by the director of health, any exemptions or 148 exclusions from taxation authorized by sections 140.08, 5709.08, 149 5709.12, 5709.121, division (B)(1) or (12) of section 5739.02, 150 and division (E)(8) of section 5751.01 of the Revised Code that 151 otherwise apply to the hospital shall cease to apply to that 1.52 hospital on and after the first day of January of the year 153 following the year in which the determination was made that the 154 hospital is no longer in compliance, notwithstanding anything to 155 the contrary in those sections. On and after that date, the real 156 property owned or held by the hospital shall become subject to 157 property taxation; purchases of tangible personal property or 158 services by the hospital shall be subject to sales and use taxes 159 levied under Chapter 5739. or 5741. of the Revised Code to the 160 extent otherwise applicable to such transactions; and the 161 hospital shall become a taxpayer for the purposes of the tax 162 levied under Chapter 5751. of the Revised Code. Such real 163

property shall continue to be taxable for each tax year until	164
the tax year preceding the tax year in which the determination	165
is made that tax-exempt status is restored; such purchases shall	166
continue to be subject to sales and use taxes levied under	167
Chapter 5739. or 5741. of the Revised Code until the first day	168
of the first month that begins after the date that determination	169
is made; and the hospital shall continue to be a taxpayer for	170
the purposes of the tax levied under Chapter 5751. of the	171
Revised Code until the first day of the tax period that begins	172
after the date that determination is made.	173
Nothing in this section affects the continued exemption	174
from taxation, under section 140.08 of the Revised Code, of	175
obligations issued under section 133.08, 140.06, or 339.15 of	176
the Revised Code or Section 3 of Article XVIII, Ohio	177
Constitution, to pay costs of hospital facilities or to refund	178
such obligations, the transfer of such obligations, the interest	179
and other income from such obligations, or any profit made on	180
their sale.	181
The director of health may adopt rules as the director	182
considers necessary to implement this section.	183
Sec. 3727.61. Each hospital shall perform, on demand and	184
regardless of ability to pay or health insurance coverage, a	185
laboratory test of liver function, the results of which may be	186
used by a person identified in division (B) of section 4731.92	187
of the Revised Code to determine whether it is appropriate to	188
administer to the person tested an injectable long-acting or	189
extended-release form of naltrexone for treatment of drug	190
addiction.	191
Sec. 3923.89. A sickness and accident insurer or public	192

Sec. 3923.89. A sickness and accident insurer or public192employee benefit plan may provide payment or reimbursement to a193

pharmacist for providing a health care service to a patient if 194 both of the following are the case: 195 (A) The pharmacist provided the health care service to the 196 patient in accordance with Chapter 4729. of the Revised Code, 197 including any of the following services: 198 (1) Managing drug therapy under a consult agreement with a 199 physician pursuant to section 4729.39 of the Revised Code; 200 201 (2) Administering immunizations in accordance with section 202 4729.41 of the Revised Code; (3) Administering drugs in accordance with section 4729.45 203 or 4731.92 of the Revised Code. 204 (B) The patient's individual or group policy of sickness 205 and accident insurance or public employee benefit plan provides 206 for payment or reimbursement of the service. 207 Sec. 4723.52. (A) As used in this section: 208 (1) "Community addiction services provider" has the same 209 meaning as in section 5119.01 of the Revised Code. 210 (2) "Medication-assisted treatment" has the same meaning 211 as in section 340.01 of the Revised Code. 212 (B) An advanced practice registered nurse shall comply 213 with section 3719.064 3719.067 of the Revised Code and rules 214 adopted under section 4723.51 of the Revised Code when treating 215 a patient for addiction with medication-assisted treatment or 216 proposing to initiate such treatment. 217 (C) An advanced practice registered nurse who fails to 218 comply with this section shall treat not more than thirty 219 patients at any one time with medication-assisted treatment even 220

if the facility or location at which the treatment is provided 221 222 is either of the following: (1) Exempted by divisions (B)(2)(a) to (d) of section 223 4729.553 of the Revised Code from being required to possess a 224 category III terminal distributor of dangerous drugs license 225 with an office-based opioid treatment classification; 226 (2) A community addiction services provider that provides 227 alcohol and drug addiction services that are certified by the 228 department of mental health and addiction services under section 229 5119.36 of the Revised Code. 230 Sec. 4729.283. (A) A pharmacist may dispense naltrexone 231 without a written or oral prescription from a licensed health 232 professional authorized to prescribe drugs if all of the 233 following conditions are met: 234 (1) The pharmacist is able to verify a record of a 235 prescription for the injectable long-acting or extended-release 236 form of naltrexone in the name of the patient who is requesting 237 the drug, but the prescription does not provide for a refill or 238 the time permitted by rules adopted by the state board of 239 pharmacy for providing refills has elapsed. 240 (2) The pharmacist is unable to obtain authorization to 241 refill the prescription from the prescriber who issued it or 242 another prescriber responsible for the patient's care. 243 (3) In the exercise of the pharmacist's professional 244 judgment: 245 (a) The drug is necessary to continue the patient's 246 therapy for substance use disorder. 247

(b) Failure to dispense the drug to the patient could 248

249

250

251

252

253

259

260

261

262

263

264

265

266

result in harm to the health of the patient. (B) Before dispensing naltrexone under this section, the pharmacist shall offer the patient the choice of receiving either the oral form or injectable long-acting or extendedrelease form, but only if both forms of the drug are available

for dispensing at the time of the patient's request or within254one day after the request.255

(C) (1) With respect to naltrexone dispensed in an oral
form under this section, the pharmacist shall not dispense an
amount that exceeds a five-day supply.
258

(2) With respect to naltrexone dispensed in an injectable long-acting or extended-release form under this section, both of the following apply:

(a) The pharmacist shall exercise professional judgment in determining the amount of the drug dispensed.

(b) The pharmacist may administer the drug by injection to the patient but only in accordance with section <u>4729.45</u><u>4731.92</u> of the Revised Code.

(D) A pharmacist who dispenses naltrexone under this 267 section shall do all of the following: 268

(1) For one year after the date of dispensing, maintain a
(1) For one year after the date of dispensing, maintain a
(1) For one year after the date of dispensing, maintain a
(1) For one year after the date of dispensing, maintain a
(1) For one year after the date of dispensing, maintain a
(1) For one year after the date of dispensing, maintain a
(1) For one year after the date of dispensing, maintain a
(1) For one year after the date of dispensing, maintain a
(1) For one year after the date of dispensing, maintain a
(1) For one year after the date of dispensing, maintain a
(1) For one year after the date of dispension, maintain a
(1) For one year after the date of dispension, maintain a
(1) For one year after the date of dispension, maintain a
(1) For one year after the date of dispension, maintain a
(1) For one year after the date of dispension, maintain a
(1) For one year after the date of dispension, maintain a
(1) For one year after the date of dispension, maintain a
(2) For one year after the date of dispensed, the original
(2) For one year after the date of dispensed, the original
(2) For one year after the date of dispensed, the original
(2) For one year after the date of dispensed, the original
(2) For one year after the date of dispensed, the original
(2) For one year after the date of dispensed, the original
(2) For one year after the date of date of dispensed, the original
(2) For one year after the date of dat

(2) Notify the prescriber who issued the prescriptiondescribed in division (A)(1) of this section or another275

five days after the drug is dispensed; 278 (3) If applicable, obtain authorization for additional 279 dispensing from one of the prescribers described in division (D) 280 (2) of this section. 281 (E) A pharmacist shall exercise professional judgment in 282 determining the number of times naltrexone may be dispensed 283 under this section to the same patient. 284 (F) This section does not limit the authority of a 285 pharmacist to dispense a dangerous drug under section 4729.281 286 of the Revised Code. 287 Sec. 4729.45. (A) As used in this section, "physician" 288 means an individual authorized under Chapter 4731. of the 289 Revised Code to practice medicine and surgery or osteopathic 290 medicine and surgery. 291 (B)(1) Subject to division (C) of this section, a 292 pharmacist licensed under this chapter may administer by 293 injection any of the following drugs as long as the drug that is 294 to be administered has been prescribed by a physician and the 295 individual to whom the drug was prescribed has an ongoing 296 physician-patient relationship with the physician: 297 (a) An opioid antagonist used for treatment of drug-298 addiction and administered in a long-acting or extended-release-299 form; 300 (b) An antipsychotic drug administered in a long-acting or 301 extended-release form; 302 303 (c) <u>(b)</u> Hydroxyprogesterone caproate; (d) (c) Medroxyprogesterone acetate; 304

prescriber responsible for the patient's care not later than

(e) <u>(d)</u>Cobalamin.	305
(2) As part of engaging in the administration of drugs by	306
injection pursuant to this section, a pharmacist may administer	307
epinephrine or diphenhydramine, or both, to an individual in an	308
emergency situation resulting from an adverse reaction to a drug	309
administered by the pharmacist.	310
(C) To be authorized to administer drugs pursuant to this	311
section, a pharmacist must do all of the following:	312
(1) Successfully complete a course in the administration	313
of drugs that satisfies the requirements established by the	314
state board of pharmacy in rules adopted under division (H)<u>(</u>G)	315
(1)(a) of this section;	316
(2) Receive and maintain certification to perform basic	317
life-support procedures by successfully completing a basic life-	318
support training course that is certified by the American red	319
cross or American heart association or approved by the state	320
board of pharmacy;	321
(3) Practice in accordance with a protocol that meets the	322

requirements of division $\frac{(F)}{(E)}$ of this section. 323

(D) Each time a pharmacist administers a drug pursuant to 324this section, the pharmacist shall do all of the following: 325

(1) Obtain permission in accordance with the procedures
 specified in rules adopted under division (H) (G) of this
 section and comply with the following requirements:
 328

(a) Except as provided in division (D) (1) (c) of this
329
section, for each drug administered by a pharmacist to an
330
individual who is eighteen years of age or older, the pharmacist
331
shall obtain permission from the individual.
332

H. B. No. 700 As Introduced

(b) For each drug administered by a pharmacist to an	333
individual who is under eighteen years of age, the pharmacist	334
shall obtain permission from the individual's parent or other	335
person having care or charge of the individual.	336
(c) For each drug administered by a pharmacist to an	337
individual who lacks the capacity to make informed health care	338
decisions, the pharmacist shall obtain permission from the	339
person authorized to make such decisions on the individual's	340
behalf.	341
(2) In the case of an opioid antagonist described in	342
division (B) of this section, obtain in accordance with division-	343
(E) of this section test results indicating that it is	344
appropriate to administer the drug to the individual if either	345
of the following is to be administered:	346
(a) The initial dose of the drug;	347
(a) The initial dose of the drug; (b) Any subsequent dose, if the administration occurs more	347 348
	-
(b) Any subsequent dose, if the administration occurs more-	348
(b) Any subsequent dose, if the administration occurs more- than thirty days after the previous dose of the drug was-	348 349
(b) Any subsequent dose, if the administration occurs more- than thirty days after the previous dose of the drug was- administered.	348 349 350
<pre>(b) Any subsequent dose, if the administration occurs more than thirty days after the previous dose of the drug was administered. (3) Observe the individual to whom the drug is</pre>	348 349 350 351
<pre>(b) Any subsequent dose, if the administration occurs more than thirty days after the previous dose of the drug was administered. (3) Observe the individual to whom the drug is administered to determine whether the individual has an adverse</pre>	348 349 350 351 352
<pre>(b) Any subsequent dose, if the administration occurs more than thirty days after the previous dose of the drug was administered. (3)-Observe the individual to whom the drug is administered to determine whether the individual has an adverse reaction to the drug;</pre>	348 349 350 351 352 353
<pre>(b) Any subsequent dose, if the administration occurs more than thirty days after the previous dose of the drug was administered. (3)-Observe the individual to whom the drug is administered to determine whether the individual has an adverse reaction to the drug; (4)-(3)_Notify the physician who prescribed the drug that</pre>	348 349 350 351 352 353 354
<pre>(b) Any subsequent dose, if the administration occurs more than thirty days after the previous dose of the drug was administered. (3) Observe the individual to whom the drug is administered to determine whether the individual has an adverse reaction to the drug; (4) (3) Notify the physician who prescribed the drug that the drug has been administered to the individual.</pre>	348 349 350 351 352 353 354 355
<pre>(b) Any subsequent dose, if the administration occurs more than thirty days after the previous dose of the drug was administered. (3)-Observe the individual to whom the drug is administered to determine whether the individual has an adverse reaction to the drug; (4)-(3)_Notify the physician who prescribed the drug that the drug has been administered to the individual. (E) A pharmacist may obtain the test results described in-</pre>	348 349 350 351 352 353 354 355 356
 (b) Any subsequent dose, if the administration occurs more than thirty days after the previous dose of the drug was administered. (3)—Observe the individual to whom the drug is administered to determine whether the individual has an adverse reaction to the drug; (4)—(3)_Notify the physician who prescribed the drug that the drug has been administered to the individual. (E) A pharmacist may obtain the test results described in division (D)(2) of this section in either of the following ways: 	348 349 350 351 352 353 354 355 356 357

If a pharmacist orders blood and urine tests, the 361 pharmacist shall evaluate the results of the tests to determine 362 whether they indicate that it is appropriate to administer the 363 opioid antagonist. A pharmacist's authority to evaluate test 364 results under this division does not authorize the pharmacist to-365 366 make a diagnosis. (F) All of the following apply with respect to the 367 protocol required by division (C)(3) of this section: 368 (1) The protocol must be established by a physician who 369 has a scope of practice that includes treatment of the condition 370 for which the individual has been prescribed the drug to be 371 administered. 372 (2) The protocol must satisfy the requirements established 373 in rules adopted under division (H) (G) (1) (b) of this section. 374 (3) The protocol must do all of the following: 375 (a) Specify a definitive set of treatment guidelines; 376 (b) Specify the locations at which a pharmacist may engage 377 in the administration of drugs pursuant to this section; 378 (c) Include provisions for implementing the requirements 379 of division (D) of this section, including for purposes of 380 division (D) $\frac{(2)}{(2)}$ of this section provisions specifying the 381 length of time and location at which a pharmacist must observe 382 an individual who receives a drug to determine whether the 383 individual has an adverse reaction to the drug; 384 (d) Specify procedures to be followed by a pharmacist when 385 administering epinephrine, diphenhydramine, or both, to an 386

individual who has an adverse reaction to a drug administered by 387 the pharmacist. 388

(G) (F) A pharmacist shall not do either of the following:	389
(1) Engage in the administration of drugs pursuant to this	390
section unless the requirements of division (C) of this section	391
have been met;	392
(2) Delegate to any person the pharmacist's authority to	393
engage in the administration of drugs pursuant to this section.	394
(H)(G)(1) The state board of pharmacy shall adopt rules to	395
implement this section. The rules shall be adopted in accordance	396
with Chapter 119. of the Revised Code and include all of the	397
following:	398
(a) Requirements for courses in administration of drugs;	399
(b) Requirements for protocols to be followed by	400
pharmacists in administering drugs pursuant to this section;	401
(c) Procedures to be followed by a pharmacist in obtaining	402
permission to administer a drug to an individual.	403
(2) The board shall consult with the state medical board	404
before adopting rules regarding requirements for protocols under	405
this section.	406
Sec. 4729.75. The state board of pharmacy may establish	407
and maintain a drug database. The board shall use the drug	408
database to monitor the misuse and diversion of the following:	409
controlled substances, as defined in section 3719.01 of the	410
Revised Code; medical marijuana, as authorized under Chapter	411
3796. of the Revised Code; and other dangerous drugs the board	412
includes in the database pursuant to rules adopted under section	413
4729.84 of the Revised Code.	414
The board also shall use the drug database to monitor	415
naltrexone, including the administration of injectable long-	416

acting or extended-release forms of naltrexone as authorized 417 under section 4731.92 of the Revised Code. 418 In establishing and maintaining the database, the board 419 shall electronically collect information pursuant to sections 420 4729.77, 4729.771, 4729.772, 4729.78, and 4729.79, and 4729.791 421 of the Revised Code and shall disseminate information as 422 authorized or required by sections 4729.80 and 4729.81 of the 423 Revised Code. The board's collection and dissemination of 424 information shall be conducted in accordance with rules adopted 425 under section 4729.84 of the Revised Code. 426 Sec. 4729.791. (A) (1) If the state board of pharmacy 427 establishes and maintains a drug database pursuant to section 428 4729.75 of the Revised Code, the following individuals who 429 administer injectable long-acting or extended-release forms of 430 naltrexone shall submit to the board the information identified 431 in division (A)(2) of this section: 432 (a) A licensed health professional authorized to prescribe 433 drugs; 434 (b) An individual identified in division (B) of section 435 4731.92. 436 (2) Each individual identified in division (A) of this 437 section shall submit the following information to the board: 438 (a) The individual's name and licensing board; 439 (b) The name of the individual receiving the drug by 440 injection; 441 (c) The date the drug was administered; 442 (d) The name, strength, and national drug code of the drug 443 furnished; 444

(e) Any other information specified by the board in rules	445
adopted under section 4729.84 of the Revised Code.	446
(B) If the state board of pharmacy establishes and	447
maintains a drug database pursuant to section 4729.75 of the	448
Revised Code, each licensed health professional who receives	449
test results indicating whether or not it is appropriate to	450
administer to an individual an injectable long-acting or	451
	452
extended-release form of naltrexone shall submit to the board	
the following:	453
(1) Health professional identification;	454
(2) Patient identification;	455
(3) Date and results of the test;	456
(4) Any other information specified by the board in rules	457
adopted under section 4729.84 of the Revised Code.	458
(C) Information required by this section shall be	459
transmitted as specified by the board in rules adopted under	460
section 4729.84 of the Revised Code.	461
The information shall be submitted electronically in the	462
format specified by the board, except that the board may grant a	463
waiver allowing the individual to submit the information in	464
another format.	465
The information shall be submitted in accordance with any	466
time limits specified by the board, except that the board may	467
grant an extension if either of the following occurs:	468
(1) The individual's transmission system suffers a	469
mechanical or electronic failure or the individual cannot meet	470
the deadline for other reasons beyond the individual's control.	471

(2) The board is unable to receive electronic submissions.	472
(D) If the board becomes aware of an individual's failure	473
to comply with this section, the board shall notify the	474
government entity responsible for licensing the individual.	475
Sec. 4729.80. (A) If the state board of pharmacy	476
establishes and maintains a drug database pursuant to section	477
4729.75 of the Revised Code, the board is authorized or required	478
to provide information from the database only as follows:	479
(1) On receipt of a request from a designated	480
representative of a government entity responsible for the	481
licensure, regulation, or discipline of health care	482
professionals with authority to prescribe, administer, or	483
dispense drugs, the board may provide to the representative	484
information from the database relating to the professional who	485
is the subject of an active investigation being conducted by the	486
government entity or relating to a professional who is acting as	487
an expert witness for the government entity in such an	488
investigation.	489
(2) On receipt of a request from a federal officer, or a	490
state or local officer of this or any other state, whose duties	491
include enforcing laws relating to drugs, the board shall	492
provide to the officer information from the database relating to	493
the person who is the subject of an active investigation of a	494
drug abuse offense, as defined in section 2925.01 of the Revised	495
Code, being conducted by the officer's employing government	496
entity.	497
(3) Pursuant to a subpoena issued by a grand jury, the	498
board shall provide to the grand jury information from the	499
database relating to the person who is the subject of an	500

investigation being conducted by the grand jury.

(4) Pursuant to a subpoena, search warrant, or court order
in connection with the investigation or prosecution of a
possible or alleged criminal offense, the board shall provide
information from the database as necessary to comply with the
subpoena, search warrant, or court order.

(5) On receipt of a request from a prescriber or the
prescriber's delegate approved by the board, the board shall
provide to the prescriber a report of information from the
database relating to a patient who is either a current patient
of the prescriber or a potential patient of the prescriber based
on a referral of the patient to the prescriber, if all of the
following conditions are met:

(a) The prescriber certifies in a form specified by theboard that it is for the purpose of providing medical treatmentto the patient who is the subject of the request;

(b) The prescriber has not been denied access to the database by the board.

(6) On receipt of a request from a pharmacist or the 519 pharmacist's delegate approved by the board, the board shall 520 provide to the pharmacist information from the database relating 521 to a current patient of the pharmacist, if the pharmacist 522 certifies in a form specified by the board that it is for the 523 purpose of the pharmacist's practice of pharmacy involving the 524 patient who is the subject of the request and the pharmacist has 525 not been denied access to the database by the board. 526

(7) On receipt of a request from an individual seeking the
individual's own database information in accordance with the
procedure established in rules adopted under section 4729.84 of
529

501

514

515

516

517

the Revised Code, the board may provide to the individual the 530 individual's own prescription history. 531

(8) On receipt of a request from a medical director or a 532 pharmacy director of a managed care organization that has 533 entered into a contract with the department of medicaid under 534 section 5167.10 of the Revised Code and a data security 535 agreement with the board required by section 5167.14 of the 536 Revised Code, the board shall provide to the medical director or 537 the pharmacy director information from the database relating to 538 a medicaid recipient enrolled in the managed care organization, 539 including information in the database related to prescriptions 540 for the recipient that were not covered or reimbursed under a 541 program administered by the department of medicaid. 542

(9) On receipt of a request from the medicaid director,
543
the board shall provide to the director information from the
544
database relating to a recipient of a program administered by
545
the department of medicaid, including information in the
546
database related to prescriptions for the recipient that were
547
not covered or paid by a program administered by the department.

(10) On receipt of a request from a medical director of a 549 managed care organization that has entered into a contract with 550 the administrator of workers' compensation under division (B)(4) 551 of section 4121.44 of the Revised Code and a data security 552 agreement with the board required by section 4121.447 of the 553 Revised Code, the board shall provide to the medical director 554 information from the database relating to a claimant under 555 Chapter 4121., 4123., 4127., or 4131. of the Revised Code 556 assigned to the managed care organization, including information 557 in the database related to prescriptions for the claimant that 558 were not covered or reimbursed under Chapter 4121., 4123., 559 4127., or 4131. of the Revised Code, if the administrator of
workers' compensation confirms, upon request from the board,
that the claimant is assigned to the managed care organization.
562

(11) On receipt of a request from the administrator of 563 workers' compensation, the board shall provide to the 564 administrator information from the database relating to a 565 claimant under Chapter 4121., 4123., 4127., or 4131. of the 566 Revised Code, including information in the database related to 567 prescriptions for the claimant that were not covered or 568 reimbursed under Chapter 4121., 4123., 4127., or 4131. of the 569 Revised Code. 570

(12) On receipt of a request from a prescriber or the prescriber's delegate approved by the board, the board shall provide to the prescriber information from the database relating to a patient's mother, if the prescriber certifies in a form specified by the board that it is for the purpose of providing medical treatment to a newborn or infant patient diagnosed as opioid dependent and the prescriber has not been denied access to the database by the board.

(13) On receipt of a request from the director of health, 579 the board shall provide to the director information from the 580 database relating to the duties of the director or the 581 department of health in implementing the Ohio violent death 582 reporting system established under section 3701.93 of the 583 Revised Code. 584

(14) On receipt of a request from a requestor described in 585 division (A)(1), (2), (5), or (6) of this section who is from or 586 participating with another state's prescription monitoring 587 program, the board may provide to the requestor information from 588 the database, but only if there is a written agreement under 589

571

572

573

574

575

576

577

618

which the information is to be used and disseminated according	590
to the laws of this state.	591
(15) On receipt of a request from a delegate of a retail	592
dispensary licensed under Chapter 3796. of the Revised Code who	593
is approved by the board to serve as the dispensary's delegate,	594
the board shall provide to the delegate a report of information	595
from the database pertaining only to a patient's use of medical	596
marijuana, if both of the following conditions are met:	597
(a) The delegate certifies in a form specified by the	598
board that it is for the purpose of dispensing medical marijuana	599
for use in accordance with Chapter 3796. of the Revised Code.	600
for abe in accordance with chapter 5750. Of the newfold code.	000
(b) The retail dispensary or delegate has not been denied	601
access to the database by the board.	602
(16) On receipt of a request from a judge of a program	603
certified by the Ohio supreme court as a specialized docket	604
program for drugs, the board shall provide to the judge, or an	605
employee of the program who is designated by the judge to	606
receive the information, information from the database that	607
relates specifically to a current or prospective program	608
participant.	609
(17) On receipt of a request from a coroner, deputy	610
coroner, or coroner's delegate approved by the board, the board	611
shall provide to the requestor information from the database	612
relating to a deceased person about whom the coroner is	613
conducting or has conducted an autopsy or investigation.	614
(18) On receipt of a request from a prescriber, the board	615
may provide to the prescriber a summary of the prescriber's	616
prescribing record if such a record is created by the board.	617

Information in the summary is subject to the confidentiality

requirements of this chapter.

(19) (a) On receipt of a request from a pharmacy's
620
responsible person, the board may provide to the responsible
person a summary of the pharmacy's dispensing record if such a
622
record is created by the board. Information in the summary is
623
subject to the confidentiality requirements of this chapter.

(b) As used in division (A) (19) (a) of this section,
"responsible person" has the same meaning as in rules adopted by
the board under section 4729.26 of the Revised Code.
627

(20) The board may provide information from the database
without request to a prescriber or pharmacist who is authorized
to use the database pursuant to this chapter.

(21) (a) On receipt of a request from a prescriber or 631 pharmacist, or the prescriber's or pharmacist's delegate, who is 632 a designated representative of a peer review committee, the 633 board shall provide to the committee information from the 634 database relating to a prescriber who is subject to the 635 committee's evaluation, supervision, or discipline if the 636 information is to be used for one of those purposes. The board 637 shall provide only information that it determines, in accordance 638 with rules adopted under section 4729.84 of the Revised Code, is 639 appropriate to be provided to the committee. 640

(b) As used in division (A) (21) (a) of this section, "peer
review committee" has the same meaning as in section 2305.25 of
the Revised Code, except that it includes only a peer review
643
committee of a hospital or a peer review committee of a
644
nonprofit health care corporation that is a member of the
645
hospital or of which the hospital is a member.

(22) Any personal health information submitted to the 647

board pursuant to section 4729.772 of the Revised Code may be648provided by the board only as authorized by the submitter of the649information and in accordance with rules adopted under section6504729.84 of the Revised Code.651

(23) On receipt of a request from an individual identified in division (B) of section 4731.92 of the Revised Code, the board shall provide to the individual a report of information from the database pertaining only to a patient's treatment for drug addiction.

(B) The state board of pharmacy shall maintain a record of
(B) The state board of pharmacy shall maintain a record of
(B) The state board of pharmacy shall maintain a record of
(B) The state board of pharmacy shall maintain a record of
(B) The state board of pharmacy shall maintain a record of
(B) The state board of pharmacy shall maintain a record of
(B) The state board of pharmacy shall maintain a record of
(B) The state board of pharmacy shall maintain a record of
(B) The state board of pharmacy shall maintain a record of
(B) The state board of
(B) The state board of
(B) The state board may
(B) The

The board may provide records of an individual's requests663for database information only to the following:664

(1) A designated representative of a government entity
(1) A designated representative of a government entity of the individual who submitted the requests
(1) A designated representative of a government entity
(2) A designated representative of a government entity
(3) A designated representative of a government entity
(4) A designated representative of a government entity
(4) A designated representative of a government entity
(5) A designated representative of a government entity
(6) A designated representative of a governmented representative of a go

(2) A federal officer, or a state or local officer of this
672
or any other state, whose duties include enforcing laws relating
673
to drugs and who is involved in an active investigation being
674
conducted by the officer's employing government entity of the
675
individual who submitted the requests for database information;
676

652

653

654

655

H. B. No. 700 As Introduced

(3) A designated representative of the department of
677
medicaid regarding a prescriber who is treating or has treated a
678
recipient of a program administered by the department and who
679
submitted the requests for database information.
680

(C) Information contained in the database and any 681 information obtained from it is confidential and is not a public 682 record. Information contained in the records of requests for 683 information from the database is confidential and is not a 684 public record. Information contained in the database that does 685 not identify a person, including any licensee or registrant of 686 the board or other entity, may be released in summary, 687 statistical, or aggregate form. 688

(D) A pharmacist or prescriber shall not be held liable in damages to any person in any civil action for injury, death, or loss to person or property on the basis that the pharmacist or prescriber did or did not seek or obtain information from the database.

Sec. 4729.84. For purposes of establishing and maintaining 694 a drug database pursuant to section 4729.75 of the Revised Code, 695 the state board of pharmacy shall adopt rules in accordance with 696 Chapter 119. of the Revised Code to carry out and enforce 697 sections 4729.75 to 4729.83 of the Revised Code. The rules shall 698 specify all of the following: 699

(A) A means of identifying each patient, each terminal
700
distributor of dangerous drugs, each purchase at wholesale of
701
dangerous drugs, and each retail dispensary licensed under
702
Chapter 3796. of the Revised Code about which information is
703
entered into the drug database;
704

(B) Requirements for the transmission of information from

Page 25

689

690

691

692

693

H. B. No. 700 As Introduced

terminal distributors of dangerous drugs, manufacturers of	706
dangerous drugs, outsourcing facilities, repackagers of	707
dangerous drugs, wholesale distributors of dangerous drugs,	708
prescribers, and retail dispensaries, and other individuals	709
required to transmit information to the board;	710
(C) An electronic format for the submission of information	711
from persons identified in division (B) of this section;	712
(D) A procedure whereby a person unable to submit	713
information electronically may obtain a waiver to submit	714
information in another format;	715
(E) A procedure whereby the board may grant a request from	716
a law enforcement agency or a government entity responsible for	717
the licensure, regulation, or discipline of licensed health	718
professionals authorized to prescribe drugs that information	719
that has been stored for three years be retained when the	720
information pertains to an open investigation being conducted by	721
the agency or entity;	722
(F) A procedure whereby a person identified in division	723
(B) of this section may apply for an extension to the time by	724
which information must be transmitted to the board;	725
(G) A procedure whereby a person or government entity to	726
which the board is authorized to provide information may submit	727
a request to the board for the information and the board may	728
verify the identity of the requestor;	729
(H) Standards for determining what information is	730
appropriate to be provided under division (A)(21) of section	731
4729.80 of the Revised Code;	732
(I) A procedure whereby the board can use the database	733
request records required by division (B) of section 4729.80 of	734

the Revised Code to document and report statistics and law 735 enforcement outcomes; 736 (J) A procedure whereby an individual may request the 737 individual's own database information and the board may verify 738 the identity of the requestor; 739 (K) A reasonable fee that the board may charge under 740 section 4729.83 of the Revised Code for providing an individual 741 742 with the individual's own database information pursuant to section 4729.80 of the Revised Code; 743 (L) The other specific dangerous drugs that, in addition 744 to controlled substances, must be included in the database; 745 (M) The types of pharmacies licensed as terminal 746 distributors of dangerous drugs that are required to submit 747 prescription information to the board pursuant to section 748 4729.77 of the Revised Code: 749 (N) Additional data fields, recognized by the American 750 society for automation in pharmacy, that licensed terminal 7.51 distributors of dangerous drugs must submit to the board 752 pursuant to section 4729.77 of the Revised Code; 753 754 (O) The information regarding medical marijuana dispensed to a patient that a retail dispensary is required to submit to 755 the board pursuant to section 4729.771 of the Revised Code; 756 (P) Requirements for the transmission of information 757 pursuant to section 4729.772 of the Revised Code and 758 requirements for the release of such information by the board; 759 (Q) Any additional information that must be submitted to 760 the board pursuant to section 4729.791 of the Revised Code. 761

Sec. 4730.56. (A) As used in this section: 762

H. B. No. 700 As Introduced

(1) "Community addiction services provider" has the same 763 meaning as in section 5119.01 of the Revised Code. 764 (2) "Medication-assisted treatment" has the same meaning 765 as in section 340.01 of the Revised Code. 766 (B) A physician assistant shall comply with section 767 3719.064 3719.067 of the Revised Code and rules adopted under 768 section 4730.55 of the Revised Code when treating a patient with 769 770 medication-assisted treatment or proposing to initiate such 771 treatment. (C) A physician assistant who fails to comply with this 772 section shall treat not more than thirty patients at any one 773 time with medication-assisted treatment even if the facility or 774 location at which the treatment is provided is either of the 775 following: 776 (1) Exempted by divisions (B)(2)(a) to (d) of section 777 4729.553 of the Revised Code from being required to possess a 778 category III terminal distributor of dangerous drugs license 779 with an office-based opioid treatment classification; 780 (2) A community addiction services provider that provides 781 alcohol and drug addiction services that are certified by the 782 department of mental health and addiction services under section 783 5119.36 of the Revised Code. 784 785 Sec. 4731.83. (A) As used in this section: (1) "Medication-assisted treatment" has the same meaning 786 as in section 340.01 of the Revised Code. 787 (2) "Physician" means an individual authorized by this 788 chapter to practice medicine and surgery or osteopathic medicine 789 and surgery. 790

(B) A physician shall comply with section 3719.064 791
3719.067 of the Revised Code and rules adopted under section 792
4731.056 of the Revised Code when treating a patient with 793
medication-assisted treatment or proposing to initiate such 794
treatment. 795

(C) A physician who fails to comply with this section
 shall treat not more than thirty patients at any one time with
 797
 medication-assisted treatment even if the facility or location
 798
 at which the treatment is provided is either of the following:
 799

(1) Exempted by divisions (B) (2) (a) to (d) of section
4729.553 of the Revised Code from being required to possess a
801
category III terminal distributor of dangerous drugs license
802
with an office-based opioid treatment classification;
803

(2) A community addiction services provider that provides
alcohol and drug addiction services that are certified by the
department of mental health and addiction services under section
5119.36 of the Revised Code.

Sec. 4731.92. (A) As used in this section, "physician"808means an individual authorized to practice medicine and surgery809or osteopathic medicine and surgery.810

(B) Notwithstanding any conflicting provision of the811Revised Code or rule adopted under it, any of the following812individuals who comply with division (C) of this section may813administer by injection, in accordance with a protocol that814meets the requirements of division (F) of this section, long-815acting or extended-release forms of naltrexone for treatment of816drug addiction:817

(1) A pharmacist licensed or otherwise authorized to818practice by the state board of pharmacy under Chapter 4729. of819

the Revised Code; 820 (2) A psychologist licensed or otherwise authorized to 821 practice by the state board of psychology under Chapter 4732. of 822 823 the Revised Code; (3) An individual licensed or otherwise authorized to 824 practice by the chemical dependency professionals board under 825 Chapter 4758. of the Revised Code; 826 (4) An individual licensed or otherwise authorized to 827 practice by the counselor, social worker, and marriage and 828 family therapist board under Chapter 4757. of the Revised Code; 829 (5) An individual licensed or otherwise authorized to 830 practice by the state board of emergency medical, fire, and 831 transportation services under Chapter 4765. of the Revised Code; 832 (6) A police officer; 833 (7) A licensed health care professional not otherwise 834 listed in this section that is specifically identified in a 835 protocol that meets the requirements of division (F) of this 836 837 section. (C) To be authorized to administer injectable long-acting 838 or extended-release forms of naltrexone pursuant to this 839 section, an individual identified in division (B) of this 840 section must do all of the following: 841 (1) Successfully complete an online course in the 842 administration of drugs that satisfies the requirements 843 established by the state medical board in rules adopted under_ 844 division (I) of this section; 845

(2) Receive and maintain certification to perform basic846life-support procedures by successfully completing a basic life-847

support training course certified by the American red cross or	848
American heart association;	849
(3) Practice in accordance with a protocol that meets the	850
requirements of division (F) of this section.	851
(D) Each time an individual administers a drug pursuant to	852
this section, the individual shall do both of the following:	853
(1) Except as provided in division (E)(2) of this section,	854
obtain in accordance with division (E) of this section test	855
results indicating that it is appropriate to administer the	856
<u>drug;</u>	857
(2) Submit to the state board of pharmacy the information	858
identified in section 4729.791 of the Revised Code.	859
(E)(1) An individual identified in division (B) of this	860
section may obtain the test results described in division (D)(1)	861
of this section in any of the following ways:	862
(a) From a physician;	863
(b) From the drug database established under section	864
4729.75 of the Revised Code;	865
(c) From a hospital;	866
(d) From the person on whom the test described in division	867

(D) (1) of this section was performed.

(2) If the individual seeking to administer a drug in 869 accordance with this section is unable to obtain test results 870 indicating that it is appropriate to administer the drug and the 871 recipient of the drug declares that the recipient is unable to 872 get the test, the individual may administer the drug to the 873 recipient for not more than sixty days. 874

(F) The protocol required by division (C)(3) of this	875
section must do both of the following:	876
(1) De established be schweisier abees werden waartige	077
(1) Be established by a physician whose regular practice	877
includes treatment of the condition for which the recipient is	878
receiving the drug to be administered;	879
(2) Satisfy the requirements established in rules adopted	880
under division (I) of this section.	881
<u>(G) An individual identified in division (B) of this</u>	882
section is not liable for damages in any civil action allegedly_	883
arising from, or subject to prosecution in any criminal	884
proceeding or professional disciplinary action for, any act or	885
omission associated with administering injectable long-acting or	886
extended-release forms of naltrexone under this section, unless	887
the act or omission constitutes willful or wanton misconduct.	888
(H) Nothing in this section requires an individual	889
(H) Nothing in this section requires an individual identified in division (B) of this section to administer a drug	889 890
identified in division (B) of this section to administer a drug	890
identified in division (B) of this section to administer a drug by injection. (I) The state medical board shall adopt rules to implement	890 891
identified in division (B) of this section to administer a drug by injection. (I) The state medical board shall adopt rules to implement this section. The rules shall be adopted in accordance with	890 891 892 893
identified in division (B) of this section to administer a drug by injection. (I) The state medical board shall adopt rules to implement this section. The rules shall be adopted in accordance with Chapter 119. of the Revised Code and include at least the	890 891 892 893 894
identified in division (B) of this section to administer a drug by injection. (I) The state medical board shall adopt rules to implement this section. The rules shall be adopted in accordance with	890 891 892 893
identified in division (B) of this section to administer a drug by injection. (I) The state medical board shall adopt rules to implement this section. The rules shall be adopted in accordance with Chapter 119. of the Revised Code and include at least the	890 891 892 893 894
identified in division (B) of this section to administer a drug by injection. (I) The state medical board shall adopt rules to implement this section. The rules shall be adopted in accordance with Chapter 119. of the Revised Code and include at least the following:	890 891 892 893 894 895
<pre>identified in division (B) of this section to administer a drug by injection. (I) The state medical board shall adopt rules to implement this section. The rules shall be adopted in accordance with Chapter 119. of the Revised Code and include at least the following:</pre>	890 891 892 893 894 895 896
<pre>identified in division (B) of this section to administer a drug by injection. (I) The state medical board shall adopt rules to implement this section. The rules shall be adopted in accordance with Chapter 119. of the Revised Code and include at least the following: (1) Requirements for online courses in the administration of drugs; (2) Requirements for protocols established under this</pre>	890 891 892 893 894 895 896 897 898
<pre>identified in division (B) of this section to administer a drug by injection. (I) The state medical board shall adopt rules to implement this section. The rules shall be adopted in accordance with Chapter 119. of the Revised Code and include at least the following:</pre>	890 891 892 893 894 895 896 897
<pre>identified in division (B) of this section to administer a drug by injection. (I) The state medical board shall adopt rules to implement this section. The rules shall be adopted in accordance with Chapter 119. of the Revised Code and include at least the following: (1) Requirements for online courses in the administration of drugs; (2) Requirements for protocols established under this</pre>	890 891 892 893 894 895 896 897 898
<pre>identified in division (B) of this section to administer a drug by injection. (I) The state medical board shall adopt rules to implement this section. The rules shall be adopted in accordance with Chapter 119. of the Revised Code and include at least the following: (1) Requirements for online courses in the administration of drugs; (2) Requirements for protocols established under this section.</pre>	890 891 892 893 894 895 896 897 898 899

section 340.20 of the Revised Code and the duties of community903addiction services providers under section 5119.362 of the904Revised Code. The rules shall be adopted in accordance with905Chapter 119. of the Revised Code.906

The director shall adopt rules under this section that907authorize the department of mental health and addiction services908to determine an advanced practice registered nurse's, physician909assistant's, or physician's compliance with section 3719.0649103719.067 of the Revised Code if such practitioner works for a911community addiction services provider.912

Sec. 5119.441. (A) The department of mental health and 913 addiction services shall procure injectable long-acting or 914 extended-release forms of naltrexone and buprenorphine directly 915 from drug manufacturers and coordinate with state, county, and 916 municipal agencies to distribute the drugs as needed to treat 917 drug-addicted individuals in this state, including distribution 918 to individuals identified in division (B) of section 4731.92 of 919 the Revised Code. The department shall require monitoring and 920 monthly administration of the drugs by boards of health, boards 921 922 of alcohol, drug addiction, and mental health services, courts, and parole and probation officers. 923

(B) The department shall contract with a licensed terminal924distributor of dangerous drugs to serve as a central pharmacy925that is responsible for obtaining statewide contract pricing and926from which political subdivisions can make direct purchases of927injectable long-acting or extended-release forms of naltrexone928and buprenorphine.929

(C) In procuring injectable long-acting or extended-930release forms of naltrexone and buprenorphine pursuant to this931section, the department may use rebates to further discount the932

drug's price.

Sec. 5164.14. The medicaid program may cover a health care	934
service that a pharmacist provides to a medicaid recipient in	935
accordance with Chapter 4729. of the Revised Code, including any	936
of the following services:	937
(A) Managing drug therapy under a consult agreement with a	938
physician pursuant to section 4729.39 of the Revised Code;	939
(B) Administering immunizations in accordance with section	940
4729.41 of the Revised Code;	941
(C) Administering drugs in accordance with section 4729.45	942
or 4731.92 of the Revised Code.	943
Section 2. That existing sections 1751.91, 3719.063,	944
3719.064, 3923.89, 4723.52, 4729.283, 4729.45, 4729.75, 4729.80,	945
4729.84, 4730.56, 4731.83, 5119.363, and 5164.14 of the Revised	946
Code are hereby repealed.	947